Acrylamide forms during cooking and is classified as a probable carcinogen in humans, mandating the need for epidemiological studies of dietary acrylamide and cancers. However, the risk of dietary acrylamide exposure to breast cancer in Japanese women has not been assessed. We investigated the association between dietary acrylamide intake and risk of breast cancer in the Japan Public Health Centerbased Prospective Study. The present study included 48 910 women aged 45-74 years who responded to a 5-year follow-up survey questionnaire. Dietary acrylamide intake was assessed using a validated food frequency questionnaire. Cox proportional hazards regression models were used to estimate hazard ratios and 95% confidence intervals. During an average of 15.4 years of follow up, 792 breast cancers were diagnosed. Energy-adjusted dietary acrylamide intake was not associated with the risk of breast cancer (adjusted hazard ratio for highest versus lowest tertile = .95, 95% confidence intervals: 0.79-1.14, P-trend = .58). Further, no significant associations were observed when stratified analyses were conducted by smoking status, coffee consumption, alcohol consumption, body mass index, menopausal status, estrogen receptor status, and progesterone receptor status. In conclusion, dietary acrylamide intake was not associated with the risk of breast cancer in this population-based prospective cohort study of Japanese women. 
glycidamide by cytochrome P450 and conjugation by GST. Both acrylamide and glycidamide can combine with DNA and cause genotoxicity. 5 From the national dietary survey in Japan in 2012, acrylamide intake was estimated by Monte Carlo simulation to be 0.166 lg/kg bodyweight per day. 6 This level is less than half of that reported in Western populations, namely 0.45 lg/kg bodyweight per day in the Dutch 7 and 0.41 lg/kg bodyweight per day in Norwegians. 8 These levels are lower than in animal studies; 9, 10 however, when the benchmark dose lower confidence limit (BMDL 10 ) is 0.31 mg/kg bodyweight per day for mammary tumors in rats, the MOE is <10 000. 2 Therefore, the Food Safety Commission of Japan is vigilant about the possibility of a carcinogenic effect of dietary acrylamide. 2 Currently, 8 studies have examined the relationship between dietary acrylamide exposure and breast cancer. [11] [12] [13] [14] [15] [16] [17] [18] A recent metaanalysis of these studies observed that dietary acrylamide intake was not associated with the risk of breast cancer. 19 However, these studies were all conducted in Western countries and no study has assessed the risk of acrylamide intake on breast cancer in Asians.
Moreover, the meta-analysis included 7 studies, and some estimates were from stratified analyses, such as in premenopausal women 16 or by hormone receptor status of breast cancer. 17 The results might therefore not be robust, and further investigation among a variety of populations with various levels of acrylamide intake may be necessary.
The aim of the present study was to investigate the association between dietary acrylamide intake and the risk of breast cancer in the JPHC Study.
| MATERIALS AND METHODS

| Study participants
The JPHC Study is a population-based prospective study which aims to investigate the associations between lifestyle and lifestyle diseases in 2 cohorts. Cohort I was launched in 1990 in Iwate, Akita, Nagano, Okinawa-Chubu, and Tokyo, whereas Cohort II was started in 1993 in Ibaraki, Niigata, Kochi, Nagasaki, Okinawa-Miyako, and
Osaka. The study protocol has been described previously. 20, 21 Participants were 140 420 inhabitants (68 722 men and 71 698 women) aged 40-69 years in the jurisdictional area of these 11 public health centers. Inhabitants in the Tokyo area were not included as participants in this study because their incidence data were not available.
The study protocol was approved by the institutional review boards of the National Cancer Center, Tokyo, Japan, Osaka University and Azabu University. The authors confirm that some access restrictions apply to the data underlying the findings.
A dietary survey using a self-administered FFQ was conducted at baseline, and at 5-and 10-year follow up. The FFQ of the 5-year follow-up survey obtained more detailed dietary information than the FFQ of the baseline survey because it included more food items and portion size options than the baseline survey questionnaire. We therefore used the 5-year follow-up survey as the starting point of the present study.
After excluding participants who were disqualified (non-Japanese nationality, incorrect late report of migration occurring before the starting point, or incorrect birth data) or had died, moved out of a study area, or were lost to follow up before the starting point, 62 750 women were eligible for participation. Of these, 52 483 women responded to the 5-year follow-up questionnaire (response rate 83.6%).
Participants with a past history of breast cancer as identified by the questionnaire (N = 478) and those diagnosed with breast cancer from the baseline survey to the time of the 5-year follow-up survey were excluded (N = 27). Participants with missing or extreme (upper and lower 2.5 percentiles) energy intake data were also excluded (N = 3068). Finally, 48 910 participants were included in the study (Figure 1 ). Tables of Food Composition in Japan. 22 A validation study of the FFQ was previously conducted by comparing intake from a 28-day DR as reference in a subcohort of the JPHC study. [23] [24] [25] Correlation coefficients of energy intake among women were 0.41 and 0.24 in Cohort I (n = 113) and II (n = 176), respectively. 23 We previously reported the validity of acrylamide intake measurement from the FFQ using this existing data and our database of measured values of acrylamide content in common Japanese foods elsewhere. 26 Briefly, we developed a database of acrylamide-containing foods commonly consumed in Japan using A Cox proportional hazards model was used to estimate HR and 95% CI of breast cancer by tertile of dietary acrylamide intake, using the lowest (T1) versus the middle (T2) or highest (T3) group.
Trends were assessed by assignment of ordinal values for tertile of dietary acrylamide intake. For further analysis, 9 quantiles were also used in the Cox proportional hazards model. Acrylamide intake was adjusted for energy intake using the residual method. HR were adjusted for the following potential confounding factors: age, PHC area, smoking status (current, past, never, or missing), alcohol intake (<150 g/wk or ≥150 g/wk), BMI (<25, ≥25, or missing), family history of breast cancer (yes or no), age at menarche (≤13, 14, 15, ≥16, or missing), age at first delivery (<26, ≥26, or missing), number of deliveries (0, 1-2, 3, ≥4, or missing), menopausal status and age at menopause (premenopause, postmenopause from age <49, postmenopause from age 50 to 54, postmenopause from >55, or missing) and exogenous hormone use (yes, no, or missing). These variables were obtained from the questionnaire, and are known or suspected risk factors for breast cancer in the JPHC study. Further, we also adjusted for physical activity (metabolic equivalents) and isoflavone intake; as the results did not substantially change, however, we did not use these variables for adjustment in the final model. In a sensitivity analysis, we repeated the same analysis after excluding 120 breast cancer cases diagnosed in the first 3 years of follow up.
To elucidate the interaction effect, we conducted stratified analysis by smoking status (current smoker, past smoker, or never smoker), coffee consumption (<1 cup/wk, 1 cup or more/wk), alcohol consumption (<150 g/wk or ≥150 g/wk), BMI (<25 or ≥25), and menopausal status at starting point (pre or postmenopause). A further stratified analysis was conducted for tumor subtype defined by ER/PR status, namely ER+, ERÀ, PR+, PRÀ, ER+/PR+, and ERÀ/PRÀ. All P-values were 2-sided and statistical significance level was set at P < .05 using SAS 9.3 (SAS Institute
Inc., Cary, NC, USA). Table 1 shows participant characteristics according to acrylamide intake. Mean (SD) dietary acrylamide intake overall was 7.0 (3.7) lg/ d, corresponding to 0.14 (0.13) lg/kg bodyweight/day. There were significant differences in the following characteristics between tertiles. The highest acrylamide intake group tended to be younger and have a lower BMI; have a higher proportion of current smoking, younger menarche, premenopausal status, and exogenous female hormone non-use; have a lower proportion of older first delivery, and non-or few deliveries; and to consume less alcohol, and more coffee, green tea, biscuits and cookies, potatoes, and vegetables.
| Characteristics of participants
There was no significant difference between tertiles in the proportion of a family history of breast cancer. Figure 2 shows the contribution of acrylamide-containing foods among the total study population. The food group with the greatest contribution was beverages (total 49%; 24% for coffee, 23% for green tea, and 2% for others), followed by confectioneries (total 19%; 13% for biscuits and cookies, 3% for chocolate, and 3% for others), potatoes and starches (total 13%; 12% for potatoes and 1%
for others), vegetables (total 11%; 4% for sweet pepper, 3% for onion, 3% for bean sprouts, and 1% for others), and cereals (total 6%; 3% for rice and 3% for others). The main contributing foods were common in each acrylamide intake group, but the trend slightly differed ( Figure 3 ). As acrylamide intake increased, the contribution from coffee, green tea, and biscuits and cookies increased, whereas that from potatoes, vegetables and rice decreased.
| Association between dietary acrylamide intake
and breast cancer Table 2 shows the results of dietary acrylamide intake and risk of breast cancer. There was no association between dietary acrylamide intake and breast cancer. Compared to the lowest group, HR (95% CI) was 1.00 (0.84-1.18) in the middle group and 0.95 (0.79-1.14) in the highest (P for trend = .58). This result was consistent with the results obtained when cases occurring within 3 years after the start of follow up were excluded.
To clarify the risk in extremely high dietary acrylamide consumers among these study participants, we conducted a further analysis between 9 quantiles of acrylamide intake ( Figure 4 ). Mean (SD) dietary acrylamide intake was 2.5 (0.7) lg/d among the lowest 9 quantile consumers and 14.6 (3.6) among the highest 9 quantile consumers. No significant association was observed. Compared to the lowest quantile, HR (95% CI) of the highest quantile was 0.91 (0.66-1.25) and P for trend was .81.
Although we also conducted stratified analyses by major confounding factors, significance associations were not observed among current or past smokers (P for trend = .64), never smokers (P for trend = .43), lower coffee consumers (P for trend = .58), coffee consumers (P for trend = .71), lower alcohol consumers (P for trend = .52), higher alcohol consumers (P for trend = .60), women with a normal BMI (P for trend = .62), obese women (P for trend = .74), premenopausal women (P for trend = .37), or postmenopausal women (P for trend = .97). Further, when stratified by estrogen receptor and progesterone receptor status, there were no significant associations among ER+ (P for trend = .99), ERÀ (P for trend = .48), PR+ (P for trend = .91), PRÀ (P for trend = .33), ER+/ PR+ (P for trend = .92), or ERÀ/PRÀ (P for trend = .35) ( Table 2) .
Additionally, there were no significant associations when stratified by green tea intake (data not shown).
| DISCUSSION
We found that dietary acrylamide intake was not associated with breast cancer risk in a large prospective cohort study among Japanese women. In addition, we also found no associations when Energy adjusted intake by residual method. The 5 prospective cohort studies and 2 case-cohort studies were conducted in Sweden, the Netherlands, the USA and the UK. 11, [13] [14] [15] [16] [17] [18] Although all studies showed no association between dietary acrylamide intake and breast cancer risk in all women, a positive association was observed in premenopausal women in the UK. The authors suggested that this positive association appears to represent a proxy for an unhealthier diet, because mean dietary acrylamide intake was less than in other countries and the main sources of dietary acrylamide intake were chips and crisps. 16 In the present study, daily mean (SD) dietary acrylamide intake was 7.0 (3.7) lg in Japanese women. Western women consume 2-3 times more acrylamide than Japanese women, and mean levels of intake among Japanese women correspond to the lowest or second lowest quintile in Western women. 11, [16] [17] [18] This low and narrow intake pattern in Japanese women may affect the association toward null. Therefore, dietary acrylamide intake does not seem to increase the risk of breast cancer in Japanese women. However, 1 reason that most studies showed no association between dietary acrylamide intake and breast cancer is that country-specific analyses failed to ensure a wide distribution of intake such that the influence of dietary acrylamide could be detected.
F I G U R E 2 Contribution of acrylamide-containing foods among all participants
The main sources in our Japanese population were coffee and green tea. Although green tea is specific for Japanese participants, coffee is also a common contributing food for acrylamide intake in Western countries. 11, 14, 18 In a meta-analysis, coffee had a weakly preventive effect on breast cancer. 36 However, no preventive or causative effect was observed for our cohort between coffee or green tea intake and breast cancer risk. 37 Further, stratified analysis by coffee or green tea consumption indicated there was no interaction effect in our study. Although coffee/green tea is the major source of acrylamide intake in Japan, the intake of coffee/green tea did not have a causative effect on breast cancer in this study.
We also found no associations when our study participants were stratified by alcohol consumption and BMI level. When acrylamide was consumed, it is partly metabolized by CYP2E1 to glycidamide, which is a more reactive compound than acrylamide. 5 In a cross-sectional study, the ratio of hemoglobin adduct concentrations of acrylamide to glycidamide differed according to alcohol drinking habit and BMI level, because the activity of CYP2E1 is affected by alcohol Multivariable Cox proportional hazard models were adjusted for age (year), area (10 public health center areas), body mass index (BMI) (<25, ≥25, or missing), family history of breast cancer (yes or no), age at menarche (≤13, 14, 15, ≥16, or missing), age at first delivery (<26, ≥26, or missing), number of deliveries (0, 1-2, 3, ≥4, or missing), menopausal status and age at menopause (premenopause, postmenopause from age <49, postmenopause from age 50 to 54, postmenopause from >55, or missing), use of exogenous female hormones (yes, no, or missing), smoking status (current or past, never, or missing), and alcohol intake (<150 g/wk or ≥150 g/wk).
F I G U R E 4
Hazard ratios (HR) of breast cancer within 9 quantiles of energy-adjusted dietary acrylamide intake. The reference group was the lowest of 9 quantiles. HR and 95% confidence intervals were adjusted for age (years), area (10 public health center areas), body mass index (<25, ≥25, or missing), family history of breast cancer (yes or no), age at menarche (≤13, 14, 15, ≥16, or missing), age at first delivery (<26, ≥26, or missing), number of deliveries (0, 1-2, 3, ≥4, or missing), menopausal status and age at menopause (premenopause, postmenopause from age <49, postmenopause from age 50 to 54, postmenopause from >55, or missing), use of exogenous female hormones (yes, no, or missing), smoking status (current or past, never, or missing), and alcohol intake (<150 g/wk or ≥150 g/wk). Numbers of cases from the lowest to the highest of 9 quantiles were 86, 83, 97, 80, 93, 95, 80, 102, and 76, respectively consumption and BMI level. 38, 39 However, we could not detect any associations in a stratified analysis. As acrylamide metabolism is also affected by polymorphisms in CYP2E1, differences in the distribution of these single-nucleotide polymorphisms (SNP) may also have affected the results. 40, 41 We also conducted stratified analysis by menopausal status and the hormone receptor status of tumors, but observed no associations between dietary acrylamide intake and breast cancer. This result is consistent with previous studies. 14, 15, 17, 18 However, the effect of trace acrylamide intake on hormone concentration in humans is currently under investigation and the results to date are not consistent.
Hogervorst et al 42 reported that the hemoglobin adduct concentration of acrylamide was positively associated with estrogen concentration in premenopausal American women whose BMI was <25. In contrast, Nagata et al 43 showed that dietary acrylamide intake assessed by FFQ was negatively related to estrogen concentration among premenopausal Japanese women. In a nested case-control study by Olesen et al, 44 the hemoglobin adduct concentration of acrylamide was positively associated with the risk of ER+ breast cancer in smokers.
Therefore, further studies are needed before the effect of acrylamide intake on the hormone-related pathway can be conclusively determined.
The major strength of the present study was its prospective cohort study design. Recall bias of exposure and confounding factors was avoided because data collection was conducted before breast cancer was diagnosed. Participants were selected from the general population, the sample size was large, the response rate to the questionnaire was acceptable (83.6%) for study settings such as this, and the loss to follow up (0.1%) was negligible. The proportion of cases ascertained by DCO was 1.9%. Furthermore, the cancer registry in the study population was of sufficient quality to reduce the possibility of misclassification of outcome.
This study has several limitations. First, there is a possibility of misclassification of acrylamide intake groups. The correlation coefficients among dietary acrylamide intake from the DR and FFQ were low to moderate and kappa coefficients in quintiles were over 0.8.
High kappa coefficients showed categorical agreement, but the possibility of the attenuation of relative risk by misclassification of exposure assessment still remains. Moreover, the JPHC study and the validation study for the FFQ were conducted in the 1990s, but we calculated acrylamide intake using the measured values of acrylamide in foods in the 2000s because measured values were not available in the 1990s. This time lag may have lead to underestimation and misclassification because of the efforts of food companies in reducing acrylamide content in foods. However, the concentrations of acrylamide in coffee, which was the most important food in total acrylamide intake, did not dramatically differ between the recent decades, 6 and the effect is therefore considered to be relatively small. Second, assessment of dietary acrylamide intake by FFQ may not reflect the true acrylamide and glycidamide exposure because acrylamide metabolism may be affected by individual enzyme activity 40 and lifestyle. 38 Further epidemiological study using biomarkers is needed to clarify acrylamide and glycidamide exposure in terms of internal dose. Third, the occurrence of breast cancer in Japan is less than in Western countries. Despite a reasonably large cohort population (48 910 women) and long follow-up period (average 15 years), the number of cases of breast cancer in this cohort was relatively small (n = 792), reflecting the low incidence rate in Japan (age-standardized rate per 100 000 world population in 2012, 51.5 in Japan and 92.9 in the USA for comparison). 45 The lack of subjects and cases may have rendered some null associations in the stratified analyses less robust, and interpretation may therefore need caution.
Fourth, other confounding factors might have affected the results.
Although we adjusted for several confounding factors in the statistical model to the maximum degree possible, the effects of unmeasured confounders cannot be totally discarded.
In conclusion, we found that there was no association between dietary acrylamide intake and breast cancer risk regardless of smoking status, coffee consumption, alcohol consumption, BMI, menopausal status, or hormone receptor status of breast cancer tumors in a large prospective cohort study among Japanese women. Our findings suggest that dietary acrylamide intake is unlikely to increase the risk of breast cancer in Japanese women. 
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